{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:01:52Z","timestamp":1780437712431,"version":"3.54.1"},"reference-count":76,"publisher":"Informa UK Limited","issue":"15","funder":[{"name":"Roche\/Genentech, Celgene, Janssen, Pharmacyclics, AbbVie, TG Therapeutics, and A2"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2016,8,31]]},"DOI":"10.2217\/fon-2016-0084","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T07:54:01Z","timestamp":1461743641000},"page":"1769-1781","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Obinutuzumab For The Treatment Of Indolent Lymphoma"],"prefix":"10.1080","volume":"12","author":[{"given":"Jennifer","family":"Edelmann","sequence":"first","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G","family":"Gribben","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.91"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_3_8_1","volume-title":"2013 Annual Meeting of the American Society of Hematology","author":"Salles G","year":"2013","unstructured":"Salles G , SeymourJF, FeugierPet al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Presented at: 2013 Annual Meeting of the American Society of Hematology. New Orleans, LA, USA, 7\u201310 December 2013 (Abstract 509)."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_3_11_1","unstructured":"Clinical Trials Database: NCT00281918. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00281918."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_3_3_14_1","unstructured":"Clinical Trials Database: NCT00769522. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00769522."},{"key":"e_1_3_3_15_1","volume-title":"2014 Annual Meeting of the American Society of Hematology","author":"Eichhorst B","year":"2014","unstructured":"Eichhorst B , FinkAM, BuschRet al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Presented at: 2014 Annual Meeting of the American Society of Hematology. San Francisco, CA, USA, 6\u20139 December 2014 (Abstract 19)."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6547"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23668"},{"key":"e_1_3_3_18_1","unstructured":"Clinical Trials Database: NCT01010061. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01010061."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.14"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_3_22_1","unstructured":"Clinical Trials Database: NCT01059630. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01059630."},{"key":"e_1_3_3_23_1","volume-title":"2015 Annual Meeting of the American Society of Clinical Oncology","author":"Sehn LH","year":"2015","unstructured":"Sehn LH , ChuaNS, MayerJet al. GADOLIN: primary results from a Phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Presented at: 2015 Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 29 May\u20132 June 2015 (Abstract 8502)."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.014"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-1963-9"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_3_3_30_1","unstructured":"Clinical Trials Database: NCT00140582. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00140582."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70311-0"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"e_1_3_3_35_1","volume-title":"2015 Annual Meeting of the American Society of Hematology","author":"Gerecitano JF","year":"2015","unstructured":"Gerecitano JF , RobertsAW, SeymourJFet al. A Phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma. Presented at: 2015 Annual Meeting of the American Society of Hematology. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 254)."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12755"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2221"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4403"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0580"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512137"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13099"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.681655"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12630"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06661.x"},{"key":"e_1_3_3_48_1","unstructured":"Clinical Trials Database: NCT01200589. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01200589."},{"key":"e_1_3_3_49_1","unstructured":"Clinical Trials Database: NCT01332968. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01332968."},{"key":"e_1_3_3_50_1","unstructured":"Clinical Trials Database: NCT00517530. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00517530."},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9718"},{"key":"e_1_3_3_53_1","unstructured":"Clinical Trials Database: NCT00576758. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00576758."},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408773"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_3_3_56_1","unstructured":"Clinical Trials Database: NCT00825149. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00825149."},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481341"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.151"},{"issue":"17","key":"e_1_3_3_59_1","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"Chan HT","year":"2003","unstructured":"Chan HT , HughesD, FrenchRRet al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res.63(17), 5480\u20135489 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2031"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913"},{"issue":"8","key":"e_1_3_3_62_1","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov A","year":"2009","unstructured":"Ivanov A , BeersSA, WalsheCAet al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest.119(8), 2143\u20132159 (2009).","journal-title":"J. Clin. Invest."},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/6179"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305847"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.133421"},{"key":"e_1_3_3_67_1","volume-title":"2015 Annual Meeting of the American Society of Hematology","author":"Pott C","year":"2015","unstructured":"Pott C , BeladaD, DanesiNet al. Analysis of minimal residual disease in follicular lymphoma patients in gadolin, a Phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed\/refractory indolent non-Hodgkin lymphoma. Presented at: 2015 Annual Meeting of the American Society of Hematology. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 397)."},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29605"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-670802"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.791"},{"key":"e_1_3_3_73_1","unstructured":"Gazyva \u00ae (obinutuzumab) full Prescribing Information. Genentech South San Francisco CA USA (2015). www.gene.com\/download\/pdf\/gazyva_prescribing.pdf."},{"key":"e_1_3_3_74_1","unstructured":"Gazyvaro \u00ae (obinutuzumab) CHMP assessment report . F Hoffmann-La Roche AG Basel Switzerland (2014). www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500171596."},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.576"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.103"},{"key":"e_1_3_3_78_1","volume-title":"2015 Annual Meeting of the American Society of Hematology","author":"Cheson BD","year":"2015","unstructured":"Cheson BD , TraskPC, GribbenJet al. primary results of the health-related quality of life assessment from the Phase III gadolin study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory, indolent non-Hodgkin lymphoma. Presented at: 2015 Annual Meeting of the American Society of Hematology. Orlando, FL, USA, 5\u20138 December 2015 (Abstract 1532)."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2016-0084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:19Z","timestamp":1719124999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2016-0084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":76,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,8,31]]}},"alternative-id":["10.2217\/fon-2016-0084"],"URL":"https:\/\/doi.org\/10.2217\/fon-2016-0084","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}